Scinai to Connect with Investors, Showcase its Innovative I&I pipeline and its Boutique cGMP Biologics CDMO during BIO-Europe Spring 2025

Core Insights - Scinai Bioservices, a CDMO unit launched by Scinai in 2024, operates from a facility in Jerusalem, Israel, featuring 1,850 square meters of clean rooms and laboratories compliant with cGMP standards [2][3] - The CDMO unit has engaged in drug development projects for various biotech companies, including upstream and downstream process development, scale-up, and drug manufacturing for clinical trials [3] - Scinai's U.S. subsidiary aims to support early-stage biotech companies by providing essential CDMO services that are currently in short supply, allowing startups to utilize government grant funding [4] Company Overview - Scinai Immunotherapeutics Ltd. is a biopharmaceutical company with two main business units: one focused on developing biological therapeutic products for inflammation and immunology, and the other providing CDMO services to early-stage biotech companies [5] - The company is actively seeking potential pharma partners interested in co-developing or in-licensing its innovative NanoAbs targeting diseases with significant unmet medical needs [7] Business Development - Scinai has partnered with Ayana Pharma to offer liposomal encapsulated drug development services, enhancing its capabilities in the CDMO sector [3] - The company is positioned to attract institutional and private investors by showcasing its value proposition in the biopharmaceutical market [7]